WO2011063774A3 - Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes - Google Patents

Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes Download PDF

Info

Publication number
WO2011063774A3
WO2011063774A3 PCT/CZ2010/000120 CZ2010000120W WO2011063774A3 WO 2011063774 A3 WO2011063774 A3 WO 2011063774A3 CZ 2010000120 W CZ2010000120 W CZ 2010000120W WO 2011063774 A3 WO2011063774 A3 WO 2011063774A3
Authority
WO
WIPO (PCT)
Prior art keywords
pectin
steroids
pharmaceutical compositions
compositions based
active substance
Prior art date
Application number
PCT/CZ2010/000120
Other languages
English (en)
Other versions
WO2011063774A2 (fr
Inventor
Vladimir Kral
Zbynek Oktabec
Josef Jampilek
Tomas Pekarek
Bohumil Proksa
Jiri Dohnal
Anna Malovikova
Anna Ebringerova
Anna Rezacova
Original Assignee
Zentiva, K.S.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zentiva, K.S. filed Critical Zentiva, K.S.
Publication of WO2011063774A2 publication Critical patent/WO2011063774A2/fr
Publication of WO2011063774A3 publication Critical patent/WO2011063774A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

La présente invention concerne un procédé permettant de fabriquer une composition pharmaceutique contenant une substance active sous la forme d'un produit d'addition (complexe) avec une pectine, éventuellement dans un mélange contenant un glucane. Le produit d'addition ainsi obtenu se caractérise par une plus grande solubilité dans l'eau par rapport à la substance pharmaceutiquement active d'origine. Le produit d'addition (complexe) constitué de la substance active et de la pectine est ensuite utilisé pour préparer une forme galénique à libération ciblée (libération lente) dans l'intestin.
PCT/CZ2010/000120 2009-11-25 2010-11-25 Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes WO2011063774A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CZ20090790A CZ302789B6 (cs) 2009-11-25 2009-11-25 Zpusob zvýšení rozpustnosti farmaceuticky aktivních látek a cílený (kontrolovaný) transport do streva
CZPV2009-790 2009-11-25

Publications (2)

Publication Number Publication Date
WO2011063774A2 WO2011063774A2 (fr) 2011-06-03
WO2011063774A3 true WO2011063774A3 (fr) 2012-01-19

Family

ID=43743524

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000122 WO2011063776A2 (fr) 2009-11-25 2010-11-25 Complexes solubles bêta-glucane-api pour utilisation pharmaceutique
PCT/CZ2010/000121 WO2011063775A2 (fr) 2009-11-25 2010-11-25 Complexes de sartans à base de pectine et compositions pharmaceutiques fabriquées à partir de ces complexes
PCT/CZ2010/000120 WO2011063774A2 (fr) 2009-11-25 2010-11-25 Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PCT/CZ2010/000122 WO2011063776A2 (fr) 2009-11-25 2010-11-25 Complexes solubles bêta-glucane-api pour utilisation pharmaceutique
PCT/CZ2010/000121 WO2011063775A2 (fr) 2009-11-25 2010-11-25 Complexes de sartans à base de pectine et compositions pharmaceutiques fabriquées à partir de ces complexes

Country Status (2)

Country Link
CZ (1) CZ302789B6 (fr)
WO (3) WO2011063776A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014176531A2 (fr) * 2013-04-27 2014-10-30 The Regents Of The University Of California Utilisation d'un co-solvant pour produire des intermédiaires réactifs à partir de biomasse
CN103622928A (zh) * 2013-11-27 2014-03-12 广西大学 一种果胶基载体材料的制备方法及其应用
CA3177229A1 (fr) 2017-08-30 2019-03-07 Antares Pharma, Inc. Formulations de triglycerides d'ester de testosterone
CN115252587A (zh) * 2022-08-19 2022-11-01 南京泛太化工医药研究所 一种口腔速溶膜及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505966A (en) * 1990-07-04 1996-04-09 Kabi Pharmacia Ab Therapeutical composition and process for its preparation
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US20060188530A1 (en) * 1998-07-24 2006-08-24 Yoo Seo H Bile preparations for gastrointestinal disorders

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4950689A (en) 1987-03-31 1990-08-21 Yang Robert K Pectin delivery system
CA2014244A1 (fr) * 1989-04-13 1990-10-13 Takeda Chemical Industries, Ltd. Composes d'anthracycline stabilises
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
GB9004950D0 (en) * 1990-03-06 1990-05-02 Kelco Int Ltd Controlled release formulation
RO107187B1 (ro) 1992-02-11 1993-10-29 Icn Galenika Sa Compoziție farmaceutica, antiacida, stabilizata și procedeu de obținere
HU213872B (en) * 1993-09-08 1997-11-28 Mta Koezponti Kemiai Kutato In Oligo- and polygalacturonate mixed complex, pharmaceutical and food compositions containing them, further process for preparing these compounds
KR0121127B1 (ko) 1994-05-09 1997-11-13 강박광 이온성 고분자 네트웍을 갖는 피부약물전달체계
ES2163000T3 (es) * 1996-01-16 2002-01-16 Advanced Polymer Systems Inc Suministro topico de farmacos al tracto gastrointestinal inferior.
IT1282381B1 (it) 1996-04-29 1998-03-20 Trans Bussan S A Nuove formulazioni di diacereina, ottenute per inclusione del principio attivo in idrogel polisaccaridi
WO1997043989A1 (fr) 1996-05-22 1997-11-27 Diversified Pharmaceuticals, Inc. Compositions, procedes et dispositifs d'administration transdermique de medicaments
US6200574B1 (en) 1996-07-08 2001-03-13 Jose A. Diaz Chemical composition for aiding the absorption, binding and elimination of undigested fat
US5891441A (en) 1996-07-08 1999-04-06 Diaz; Jose A. Chemical composition and method for more rapidly aiding the absorption, binding an elimination of undigested fat in the human body
FR2752843B1 (fr) * 1996-08-30 1998-10-16 Sod Conseils Rech Applic Copolymeres reticules a base de polymeres polycarboxyliques et leur utilisation comme support de composition pharmaceutique
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US20040136961A1 (en) 1997-10-09 2004-07-15 Ales Prokop Nanoparticulate composition for efficient gene transfer
US6337091B1 (en) * 1997-10-27 2002-01-08 Temple University - Of The Commonwealth System Of Higher Education Matrix for controlled delivery of highly soluble pharmaceutical agents
JP4754067B2 (ja) 1997-12-02 2011-08-24 アルキメデス ディヴェロプメント リミテッド 鼻孔投与用組成物
US6313103B1 (en) 1998-05-13 2001-11-06 Carrington Laboratories, Inc. Pectic substance as a growth factor stabilizer
KR20000011247A (ko) 1998-07-23 2000-02-25 김윤 다당류를이용한대장선택성약물전달조성물및약학제제
GB9822170D0 (en) 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
RU2169002C2 (ru) 1999-04-19 2001-06-20 Пятигорская государственная фармацевтическая академия Способ получения инулин-пектинового концентрата в порошке для медицинских и пищевых целей из высушенного сырья
WO2002047612A2 (fr) 2000-10-27 2002-06-20 Mannatech, Inc. Compositions de complement alimentaire
US20030157161A1 (en) * 2001-05-01 2003-08-21 Angiotech Pharmaceuticals, Inc. Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
EP1404332A1 (fr) 2001-07-06 2004-04-07 Penwest Pharmaceuticals Company Procedes de preparation de compositions a liberation entretenue d'oxymorphone
DE60206940T2 (de) 2001-09-03 2006-04-20 Dsm Ip Assets B.V. Pektin und ascorbinsäure enthaltende zusammensetzungen
JP2003127783A (ja) 2001-10-25 2003-05-08 Mitsuboshi Belting Ltd フロアコンソール
DE10212553A1 (de) 2002-03-16 2003-09-25 Knoell Hans Forschung Ev Verwendung einer Formulierung zur in situ Biodegradation von Wundabdeckungen
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US20050089572A1 (en) 2002-03-22 2005-04-28 Manoj Kumar Controlled release drug delivery system of pravastatin
DE20205184U1 (de) 2002-03-27 2002-12-19 Bartz, Volker, 35440 Linden Blutfettsenker zur oralen Einnahme
DE10214005A1 (de) 2002-03-27 2003-10-09 Volker Bartz Blutfettsenker zur oralen Einnahme, bestehend aus einem Gemisch aus den Omega-3-Fettsäuren EPA (Eicosapentaensäure) und DHA (Docosapentaensäure) und Pektin und/oder Guar als wirksame Substanzen, sowie gegebenenfalls zusätzlichen Stoffen wie antioxidative Vitamine, Aminosäuren und Spurenelemente
DE10250083A1 (de) 2002-06-17 2003-12-24 Gruenenthal Gmbh Gegen Missbrauch gesicherte Darreichungsform
KR100522239B1 (ko) * 2002-07-16 2005-10-18 주식회사 서울제약 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
JP2004059440A (ja) 2002-07-25 2004-02-26 Mikasa Seiyaku Co Ltd 肌荒れ防止および粘膜修復剤
US20040087514A1 (en) 2002-09-06 2004-05-06 Hughes Thomas E Nutritional compositions
JP2004107295A (ja) 2002-09-20 2004-04-08 National Agriculture & Bio-Oriented Research Organization ヒスタミン遊離抑制剤
US6703044B1 (en) 2002-10-25 2004-03-09 Dexcel Pharma Tech, Ltd Venlafaxine formulations
CZ296475B6 (cs) 2002-12-09 2006-03-15 Mikrobiologický Ústav Av Cr Zpusob fermentacní prípravy extracelulárního glukanu pomocí hub Claviceps sp.
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040241223A1 (en) 2003-05-27 2004-12-02 David Wong Oral dosage forms for macromolecular drugs
CN100477999C (zh) 2003-12-29 2009-04-15 湖南华纳大药厂有限公司 胶体果胶铋分散片
IL160095A0 (en) 2004-01-28 2004-06-20 Yissum Res Dev Co Formulations for poorly soluble drugs
WO2005084648A1 (fr) * 2004-02-27 2005-09-15 Ranbaxy Laboratories Limited Compositions pharmaceutiques comprenant du candesartan cilexetil
WO2005084703A1 (fr) 2004-03-09 2005-09-15 Nrl Pharma, Inc. Composition a liberation soutenue pour cavite buccale
DE102004019916A1 (de) 2004-04-21 2005-11-17 Grünenthal GmbH Gegen Missbrauch gesichertes wirkstoffhaltiges Pflaster
WO2005105040A2 (fr) 2004-04-26 2005-11-10 Micelle Products, Inc. Preparation hydrosoluble de vitamines liposolubles, agents pharmaceutiques et leurs applications
BRPI0512394A (pt) 2004-06-22 2008-03-11 Pro Pharmaceuticals Inc composições e métodos para co-distribuição de fármacos anticáncer, fármacos antiangiogênicos e um polissacarìdeo
EP1778169A1 (fr) * 2004-08-13 2007-05-02 Symrise GmbH & Co. KG Beta-(1,3)-beta-(1,4)-glucan en tant que vehicule pour des substances chimiques
CN101128187A (zh) * 2005-02-09 2008-02-20 达沃尔泰拉公司 活性剂的结肠递送
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
DK1883396T3 (da) 2005-05-18 2013-10-07 Centre Nat Rech Scient Afgivelse af adsorptionsmidler til tyktarmen
CN100340295C (zh) 2005-06-29 2007-10-03 山西安特生物制药股份有限公司 一种口服复方胶体果胶铋制剂及制备方法
ES2279695B1 (es) 2005-08-01 2008-08-01 Jesus Antas Pharma, S.A. Nuevas formulaciones solidas de carotenoides y procedimiento para su obtencion.
JP4817042B2 (ja) 2005-08-26 2011-11-16 国立大学法人三重大学 Ａｌを含むＩＩＩ族窒化物結晶の作製方法、およびＡｌを含むＩＩＩ族窒化物結晶
US20070167395A1 (en) 2006-01-17 2007-07-19 Isaac Eliaz Compositions and methods for treating diabetes
KR101234799B1 (ko) * 2006-02-07 2013-02-20 삼성전자주식회사 이동 로봇 제어 장치 및 방법
KR100912680B1 (ko) * 2006-03-16 2009-08-19 (주) 벡스코아 제어 방출 제형
CN101045163B (zh) 2006-03-29 2011-03-30 重庆莱美药业股份有限公司 一种高分子抗癌前药及其制备方法和用途
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
CN100394923C (zh) 2006-05-26 2008-06-18 范晓青 低分子柑桔果胶用于调节血糖血脂和改善脂肪肝中的应用
US20070292480A1 (en) 2006-06-14 2007-12-20 Conopco, Inc., D/B/A Unilever Delivery System for Ingestible Components
JP2010502698A (ja) * 2006-09-05 2010-01-28 アストラゼネカ アクチボラグ カンデサルタンシレキセチルを含む医薬組成物
BRPI0719319A2 (pt) 2006-11-17 2014-02-04 Da Volterra Liberação colônica usando contas de zn/pectina com um revestimento de eudragit
RU2009141539A (ru) * 2007-04-25 2011-05-27 Тева Фармасьютикал Индастриес Лтд. (Il) Комплекс фармацевтического наполнителя
EP2172193A1 (fr) * 2008-10-02 2010-04-07 Capsulution Nanoscience AG Compositions de nanoparticules améliorées de composés faiblement solubles
CZ20098A3 (cs) 2009-01-13 2010-07-21 Zentiva, K.S. Lékové formy inhibitoru tyrosinových kináz

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5505966A (en) * 1990-07-04 1996-04-09 Kabi Pharmacia Ab Therapeutical composition and process for its preparation
US5849327A (en) * 1994-07-29 1998-12-15 Advanced Polymer Systems, Inc. Delivery of drugs to the lower gastrointestinal tract
US20060188530A1 (en) * 1998-07-24 2006-08-24 Yoo Seo H Bile preparations for gastrointestinal disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DONALD E. CADWALLADER ET AL: "Effect of macromolecules on aqueous solubility of cholesterol and hormone drugs", JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 70, no. 4, 1 April 1981 (1981-04-01), pages 442 - 446, XP055013096, ISSN: 0022-3549, DOI: 10.1002/jps.2600700426 *
GARCIA ROJAS ET AL: "Cholesterol removal in liquid egg yolk using high methoxyl pectins", CARBOHYDRATE POLYMERS, APPLIED SCIENCE PUBLISHERS, LTD. BARKING, GB, vol. 69, no. 1, 30 March 2007 (2007-03-30), pages 72 - 78, XP022009490, ISSN: 0144-8617, DOI: 10.1016/J.CARBPOL.2006.09.004 *

Also Published As

Publication number Publication date
WO2011063775A3 (fr) 2012-01-26
CZ302789B6 (cs) 2011-11-09
CZ2009790A3 (cs) 2011-06-01
WO2011063775A2 (fr) 2011-06-03
WO2011063776A3 (fr) 2012-05-31
WO2011063774A2 (fr) 2011-06-03
WO2011063776A2 (fr) 2011-06-03

Similar Documents

Publication Publication Date Title
MX2010010647A (es) Proceso para preparar formulaciones de dabigatran para administracion oral.
WO2012079092A3 (fr) Compositions d'undécanoate de testostérone
NZ599594A (en) Fast dissolving solid dosage form
WO2010039762A3 (fr) Compositions pharmaceutiques comprenant des composés d'acide boronique
NZ734152A (en) Compounds, compositions and methods useful for cholesterol mobilisation
MX2011011871A (es) Formulacion intravenosa con cocristales solubles en agua de acido acetilisalicilico y teanina.
MX2011007817A (es) Formulacion farmaceutica o alimenticia de liberacion controlada y proceso para su preparacion.
WO2013055899A3 (fr) Compositions utiles pour le traitement d'une néphropathie et leurs procédés de préparation
WO2010097243A3 (fr) Procédé de fabrication de formes posologiques orales de solifénacine et de ses sels pharmaceutiquement acceptables
AR082566A1 (es) Formulaciones liquidas de st-246 y metodos relacionados, proceso
WO2010089361A3 (fr) Procédé de préparation d'une composition pharmaceutique contenant de l'ézétimibe
MX2022003486A (es) Composiciones terapeuticas de ceramidasa acida y metodos para prepararlas y utilizarlas.
WO2011063774A3 (fr) Complexes stéroïdes à base de pectine et compositions pharmaceutiques réalisées à partir de ces complexes
WO2011081373A3 (fr) Procédé de préparation de docétaxel cristallin anhydre hautement pur
CN105616178A (zh) 一种花露水
WO2011056775A3 (fr) Compositions de cellulose microcristalline et de phosphate de calcium utiles en tant qu'excipients pharmaceutiques
WO2010020799A3 (fr) Composition
IN2012DN02576A (fr)
GB201309925D0 (en) Preparation method for caspofungin analog
WO2009155070A3 (fr) Compositions et procédés pour le traitement d’inflammation et de lésions hyperkératotiques
MX359887B (es) Composicion masticable para administracion oral y proceso para preparar la misma.
WO2011031099A3 (fr) Hybride hydrotalcite-eudragit synthétique comprenant l'acide ursodésoxycholique, composition pharmaceutique le contenant et son procédé de préparation
WO2014006635A3 (fr) Compositions orales solides de silodosine
WO2012019428A8 (fr) Dérivés de benzohydrol, procédé de préparation et utilisation pharmaceutique de ceux-ci
WO2012077968A3 (fr) Formulation complexe contenant de l'hydrochlorure de lercanidipine et du valsartan et son procédé de préparation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10810843

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 10810843

Country of ref document: EP

Kind code of ref document: A2